# Microencapsulated Tributyrin (Core Butyrate 500mg) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Triglyceride ester supplying bioactive butyric acid directly to colonic epithelial cells.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **82/100**
- **Evidence Quality Tier**: **bronze**
- **Human Clinical Evidence Strength**: 69/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 84/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: free
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Butyric acid cannot reach the colon in free form due to rapid upper GI absorption. Tributyrin provides three butyrate molecules bonded to glycerol, bypassing stomach acid to fuel colonocyte mitochondrial beta-oxidation and enforce tight junction assembly.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Heart Health & Endothelial Function**: **72/100** [Rank #66 of 133 in Heart] - Effect: Vascular anti-atherosclerotic remodeling via systemic GPR41/43 signaling
    - Mechanism: Systemic butyrate suppresses aortic vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1).
- **Brain Longevity & Neuroprotection**: **70/100** [Rank #93 of 141 in Brain] - Effect: Upregulation of hippocampal brain-derived neurotrophic factor (BDNF)
    - Mechanism: HDAC inhibition promotes promoter histone acetylation of the BDNF gene across the gut-brain axis.
- **Metabolic Flexibility & Glycemic Control**: **84/100** [Rank #24 of 129 in Metabolic] - Effect: +22% increase in mitochondrial fatty acid beta-oxidation and gut peptide secretion
    - Mechanism: Activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) signaling, maintaining physiological colonic hypoxia.
- **Cancer Defense & DNA Repair**: **80/100** [Rank #13 of 120 in Cancer Defense] - Effect: Selectively arrests cell cycle and induces apoptosis in transformed colorectal cells
    - Mechanism: The "Warburg Paradox": in cancerous colonocytes relying on glycolysis, butyrate accumulates and acts as a potent HDAC inhibitor upregulating p21.
- **Endocrine & Anabolic Balance**: **0/100** [Rank #116 of 120 in Endocrine] - Effect: No direct effect on gonadotropin or testosterone secretion.
    - Mechanism: Non-steroidal postbiotic active exclusively in intestinal mucosa.
- **Chronic Inflammation Reduction**: **88/100** [Rank #22 of 126 in Inflammation] - Effect: -40% reduction in colonic mucosal inflammatory cytokine release
    - Mechanism: Inhibits NF-kB nuclear translocation and histone deacetylases (HDAC1/HDAC3) in lamina propria dendritic cells.
- **Bone Density & Connective Matrix**: **0/100** [Rank #137 of 142 in Bone Matrix] - Effect: Neutral direct osteoblast bone formation.
    - Mechanism: No direct skeletal mechanical load or calcium receptor activation.
- **Cellular Longevity & Autophagy**: **76/100** [Rank #87 of 131 in Cellular] - Effect: Epigenetic histone acetylation of longevity-associated FoxO transcription factors
    - Mechanism: Direct non-competitive HDAC inhibition increases chromatin accessibility for DNA damage repair enzymes.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 500mg twice daily with food (1,000mg total)
- **Recommended Timing**: Twice daily with meals (Breakfast & Dinner)
- **Administration Type**: supplement
- **Recommended Biomarkers to Monitor**: Metabolic and inflammatory panel

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: 
- **Safety Profile**: high_safety - Well tolerated within physiological ranges.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Verified PubMed Literature Anchor** [PMID: 31464303]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31464303/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Microencapsulated Tributyrin (Core Butyrate 500mg) on LongevityReviews](https://longevityreviews.org/modalities/microencapsulated-tributyrin)
- **Last Evidence Calibration**: 2026-09-10
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.